Personalis's - PSNL market analysis on 22nd January 2021

Transaction Date	Recipient	Shares	Type	Price	Value
17th December 2020	Richard Chen	1,087	Open or private sale	$36.37	$39,534.19
17th December 2020	Aaron Tachibana	2,391	Open or private sale	$36.37	$86,960.67
20th October 2020	Llp Abingworth	130,486	Open or private sale	$27.66	$3,609,242.76
19th October 2020	Llp Abingworth	196,423	Open or private sale	$27.86	$5,472,344.78
16th October 2020	Llp Abingworth	94,218	Open or private sale	$26.68	$2,513,736.24
15th October 2020	Llp Abingworth	3,700	Open or private sale	$26.32	$97,384.00
14th October 2020	Llp Abingworth	81,925	Open or private sale	$27.08	$2,218,529.00
13th October 2020	Llp Abingworth	86,819	Open or private sale	$28.43	$2,468,264.17
12th October 2020	Llp Abingworth	115,541	Open or private sale	$29.09	$3,361,087.69
1st October 2020	Richard Chen	37,452	Exercise of derivative	$0.44	$16,478.88

Personalis

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

Personalis, Inc. provides genomic sequencing and analytics solutions to support the development of personalized cancer vaccines. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West and Russ B. Altman in 2011.

Ticker: PSNL

Sector: Health Technology

Industry: Biotechnology

SEC Central Index Key (CIK): 1527753

Employees: 182

Exchange: NASDAQ

Auditor Opinion:

You must Login to see Language Changes

Disclosure Language changes

Analysis of subtle changes in disclosure language. Red is a sign of more constrained, less positive language changes etc. Green is more positive, less constrained etc.

You must Login to see analysis